Trial reportPediatric blood & cancer2016
Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee.
Trial report in Pediatric blood & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04890067 (Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma
Who cites it
27 citing papers in PubMed.
- Trial
- An international framework for clinical translation of molecular classifiers in osteosarcoma.NPJ precision oncology · 2026Article
- Reply to Letter to the Editor: Deep learning for accurate tumour volume measurement and prediction of therapy response in paediatric osteosarcoma.European radiology · 2026Article
- Deep learning for accurate tumour volume measurement and prediction of therapy response in paediatric osteosarcoma.European radiology · 2026Article
- Prognostic value of 18F-FDG PET/CT derived metabolic parameters in pediatric osteosarcoma.Annals of nuclear medicine · 2026Article
- sB7-H3 as a prognostic biomarker in osteosarcoma: insights into clinical outcomes.Scientific reports · 2026Article
- Inhibition of DKK-1 by WAY262611 Inhibits Osteosarcoma Metastasis.Molecular cancer therapeutics · 2025Article
- Clinical Progression on Neoadjuvant Chemotherapy: An Indicator of Poor Outcomes in Extremity Osteosarcoma.Indian journal of surgical oncology · 2025Article
- Causal effect of chemotherapy received dose intensity on survival outcome: a retrospective study in osteosarcoma.BMC medical research methodology · 2024Article
- Article
- Dynamic Prediction of Overall Survival for Patients with Osteosarcoma: A Retrospective Analysis of the EURAMOS-1 Clinical Trial Data.Current oncology (Toronto, Ont.) · 2024Article
- Evaluation of response to neoadjuvant chemotherapy in osteosarcoma using dynamic contrast-enhanced MRI: development and external validation of a model.Skeletal radiology · 2024Article
- Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma.Scientific reports · 2023Article
- Imaging evaluation of blood supply changes after chemotherapy of osteosarcoma and its correlation with tumor necrosis rate.Journal of bone oncology · 2023Article
- CT features of osteosarcoma lung metastasis: a retrospective study of 127 patients.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023Article
- Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.International journal of molecular sciences · 2022Review
- Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma.Communications biology · 2022Article
- What Effect Do Pulmonary Micronodules Detected at Presentation in Patients with Osteosarcoma Have on 5-Year Overall Survival?Journal of clinical medicine · 2021Article
- Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.International journal of surgical oncology · 2021Article
- A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.Journal of orthopaedic surgery and research · 2020Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
backgroundThe prognostic value of histologic response for osteosarcoma may have changed with induction chemotherapy schedules over time. We hypothesized that the increased intensity of induction therapy provided on INT0133 compared to the Children's Cancer Group study CCG-782 would diminish the impact of histologic response on the risk of events after definitive surgery.
methodsRetrospective analysis was performed for patients aged <22 with newly diagnosed nonmetastatic osteosarcoma enrolled on CCG-782 and INT0133. Clinical factors were evaluated for association with response and outcome. Good response was defined as <5% viable tumor at resection. Associations of response, study, and postdefinitive surgery event-free survival (EFS-DS) were determined using Cox proportional hazard models. EFS-DS was estimated by Kaplan-Meier methodology.
resultsData were available for 814 patients (206 CCG-782, 608 INT0133). For good responders, 10-year EFS-DS (±SE) was 75.4% ± 7.7% for CCG-782 and 70.8% ± 3.1% for INT0133. For poor responders, 10-year EFS-DS was 39.9% ± 4.9% for CCG-782 and 58.4% ± 3.1% for INT0133. Histologic response predicted outcome across studies (P < 0.0001). Significant interaction between study and histologic response was observed for EFS-DS (P = 0.011). Using proportional hazards regression, INT0133 poor responders had less risk of events compared to CCG-782 poor responders (relative hazard ratio (RHR) = 0.6:1), but good responders on INT0133 had a greater risk of events compared to CCG-782 good responders (RHR = 1.53:1).
conclusionWe observed an inverse relationship between the predictive value of tumor necrosis and intensity of induction therapy, raising questions about the true prognostic value of histologic response. This highlights the need for novel markers to develop strategies for treatment in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.